Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 3/2017

01-06-2017 | Research Letter

Leptin directly stimulates parathyroid hormone secretion

Authors: Ignacio Lopez, Carmen Pineda, Ana I. Raya, Maria E. Rodriguez-Ortiz, Juan M. Diaz-Tocados, Rafael Rios, Juan M. Rodriguez, Escolastico Aguilera-Tejero, Yolanda Almaden

Published in: Endocrine | Issue 3/2017

Login to get access

Excerpt

Leptin is best known for its modulatory effects on food intake [1] but also participates in the regulation of calciotropic hormones. Leptin has been reported to stimulate bone secretion of fibroblast growth factor 23 (FGF23) [2], a major phosphaturic hormone, and to decrease 1,25(OH)2-vitamin D3 both directly, by decreasing 1-alpha-hydroxylase activity in the kidney, and indirectly, through increasing levels of FGF23 [2, 3]. …
Literature
1.
Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold, J.M. Friedman, Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425–432 (1994)CrossRefPubMed
2.
K. Tsuji, T. Maeda, T. Kawane, A. Matsunuma, N. Horiuchi, Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D3 synthesis in leptin-deficient mice. J. Bone Miner. Res. 25, 1711–1723 (2010)CrossRefPubMed
3.
A. Matsunuma, T. Kawane, T. Maeda, S. Hamada, N. Horiuchi, Leptin corrects increased gene expression of renal 25-hydroxyvitamin D3-1alpha-hydroxylase and -24-hydroxylase in leptin-deficient, ob/ob mice. Endocrinology 145, 1367–1375 (2004)CrossRefPubMed
4.
S.P. Cheng, G.M. Doherty, Y.C. Chang, C.L. Liu, Leptin: the link between overweight and primary hyperparathyroidism?. Med. Hypotheses 76, 94–96 (2011)CrossRefPubMed
5.
E. Grethen, K.M. Hill, R. Jones, B.M. Cacucci, C.E. Gupta, A. Acton, R.V. Considine, M. Peacock, Serum leptin, parathyroid hormone, 1,25-dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity. J. Clin. Endocrinol. Metab. 97, 1655–1662 (2012)CrossRefPubMedPubMedCentral
6.
D. Hoang, N. Broer, S.A. Roman, X. Yao, N. Abitbol, F. Li, J.A. Sosa, G.R. Sue, A.T. DeWan, M.L. Wong, J. Licinio, C. Simpson, A.Y. Li, N. Pizzoferrato, D. Narayan, Leptin signaling and hyperparathyroidism: clinical and genetic associations. J. Am. Coll. Surg. 218, 1239–1250 (2014)CrossRefPubMed
7.
M. Maetani, G. Maskarinec, A.A. Franke, R.V. Cooney, Association of leptin, 25-hydroxyvitamin D, and parathyroid hormone in women. Nutr. Cancer 61, 225–231 (2009)CrossRefPubMedPubMedCentral
8.
Y. Almaden, A. Canalejo, A. Hernandez, E. Ballesteros, S. Garcia-Navarro, A. Torres, M. Rodriguez, Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J. Bone Miner. Res. 11, 970–976 (1996)CrossRefPubMed
9.
K. Takaya, Y. Ogawa, N. Isse, T. Okazaki, N. Satoh, H. Masuzaki, K. Mori, N. Tamura, K. Hosoda, K. Nakao, Molecular cloning of rat leptin receptor isoform complementary DNAs—identification of a missense mutation in Zucker fatty (fa/fa) rats. Biochem. Biophys. Res. Commun. 225, 75–83 (1996)CrossRefPubMed
10.
I.Z. Ben-Dov, H. Galitzer, V. Lavi-Moshayoff, R. Goetz, M. Kuro-o, M. Mohammadi, R. Sirkis, T. Naveh-Many, J. Silver, The parathyroid is a target organ for FGF23 in rats. J. Clin. Invest. 117, 4003–4008 (2007)PubMedPubMedCentral
11.
T. Krajisnik, P. Björklund, R. Marsell, O. Ljunggren, G. Akerström, K.B. Jonsson, G. Westin, T.E. Larsson, Fibroblast growth factor-23 regulates parathyoid hormone and 1alpha-hydroxylase expression in culture bovine parathyroid cells. J. Endocrinol. 195, 125–131 (2007)CrossRefPubMed
12.
M.J. Bolland, A.B. Grey, G.D. Gamble, I.R. Reid, Association between primary hyperaparathyroidism and increased body weight: a meta-analysis. J. Clin. Endocrinol. Metab. 90, 1525–1530 (2005)CrossRefPubMed
13.
A. Taniguchi, K. Kataoka, T. Kono, F. Oseko, H. Okuda, I. Nagata, H. Imura, Parathyroid hormone-induced lipolysis in human adipose tissue. J. Lipid Res. 28, 490–494 (1987)PubMed
14.
Z. Ni, M. Smogorzewski, S.G. Massry, Effects of parathyroid hormone on cytosolic calcium of rat adipocytes. Endocrinology 135, 1837–1844 (1994)CrossRefPubMed
15.
Y. Jiang, J. Zhang, Y. Yuan, X. Zha, C. Xing, C. Shen, Z. Shen, C. Qin, M. Zeng, G. Yang, H. Mao, B. Zhang, X. Yu, B. Sun, C. Ouyang, X. Xu, Y. Ge, J. Wang, L. Zhang, C. Cheng, C. Yin, J. Zhang, H. Chen, H. Ma, N. Wang, Association of increased serum leptin with ameliorated anemia and malnutrition in stage 5 chronic kidney disease patients after parathyroidectomy. Sci. Rep. 6, 27918 (2016)CrossRefPubMedPubMedCentral
Metadata
Title
Leptin directly stimulates parathyroid hormone secretion
Authors
Ignacio Lopez
Carmen Pineda
Ana I. Raya
Maria E. Rodriguez-Ortiz
Juan M. Diaz-Tocados
Rafael Rios
Juan M. Rodriguez
Escolastico Aguilera-Tejero
Yolanda Almaden
Publication date
01-06-2017
Publisher
Springer US
Published in
Endocrine / Issue 3/2017
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-1207-z

Other articles of this Issue 3/2017

Endocrine 3/2017 Go to the issue

Original Article

Growth Hormone differentially modulates chemoresistance in human endometrial adenocarcinoma cell lines

Original Article

Tadalafil improves lean mass and endothelial function in nonobese men with mild ED/LUTS: in vivo and in vitro characterization

Editorial

Hypersexuality in men with prolactinomas treated with dopamine agonists

Letter to the Editor

Values and limitations of the comparing thyroid radiofrequency and microwave ablation using propensity score

Original Article

Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study

Original Article

Association between lifestyle and anthropometric parameters and thyroid nodule features
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits